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Résumé 
Polymorphismes ABCB1 et cytochrome P450: 
Pharmacogénétique clinique de la clozapine 
(ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of 
clozapine) 
Dans le but d'examiner les facteurs génétiques qui influencent la pharmacocinétique de la 
clozapine in vivo, 75 patients traités avec ce médicament antipsychotique ont été genotypés 
pour les polymorphismes GYP et ABCB1, et phénotypés pour l'activité de CYP1A2 et 
CYP3A. L'activité de CYP1A2 et les taux plasmatiques de clozapine en steady-state 
corrèlent d'une manière significative (r=0.61; p=1x10-6), sans influence du génotype de 
CYP1A2*1F (p=0.38). Les métaboliseurs déficients CYP2C19 (génotype *21*2 genotype) 
avaient des concentrations de clozapine 2,3 fois (p=0.036) plus élevées que les 
métaboliseurs rapides (non*2/*2). Chez les patients comédiqués avec la fluvoxamine, un fort 
inhibiteur de CYP1A2, les concentrations de clozapine et de norclozapine corrèlent 
siginificativement avec l'activité de CYP3A (r=0.44, p=0.075; r=0.63, p=0.007, 
respectivement). Les porteurs du génotype ABCB1 3435TT avaient des concentrations 
plasmatiques de clozapine 1,6 fois plus élevées que ceux qui ne présentaient pas ce 
génotype (p=0.046). En conclusion, cette étude montre pour la première fois, in vivo, le rôle 
significatif de CYP2C19 et celui du transporteur P-gp dans la pharmacocinétique de la 
clozapine. Le CYP1A2 est la forme principale de CYP impliquée dans le métabolisme de 
clozapine, tandis que le CYP2C19 joue un rôle modéré et que le CYP3A4 n'y contribue que 
chez les patients qui présentent une activité de CYP1 A2 réduite. De plus, le polymorphisme 
de ABCB1, mais pas ceux de CYP286, CYP2C9, CYP206, CYP3A5 et CYP3A7, influence 
la pharmacocinétique de la clozapine. 
Mots-clé: clozapine; concentration plasmatique; CYP1A2; CYP2C19; CYP3A4; ABCB1 
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ABCB1 and Cytochrome P450 Polymorphisms 
Clinica/ Pharmacogenetics of Clozapine 
. Eveline Jaquenoud Sirat, MSc, * Branka Knezevic, MD,* Gina Perla Morena, MD, t 
Sabine Harenberg, PhD, *Beatrice Oneda, PhD,:f: Séverine Crettol, PhD,:f: Nicolas Ansermot, PhD,:f: 
Pierre Baumann, PhD,:f: and Chin B, Eap, PhD:f:§ 
Abstract: To examine the genetiC factors influencing clozapine 
kinetics in vivo, 75 patients treated with clozapine were genotyped 
for CYPs and ABCBI polymorphisms and phenotyped for CYP1A2 
and CYP3A activity. CYP1A2 activity and dose-corrected trough 
steady-state plasma concentrations of clozapine correlated significantly 
(r = -0.61; P = 1 x 10-6), with no.influence of the CYPIA2*/F 
genotype (P = 0.38). C.YP2C 19 poor metabolizers (*2/*2 genotype) had 
2.3-fold higher (P = 0.036) clozapihe concentrations than the extensive 
metabolizers (non-*2/*2). In patients comedicated with fluvoxamine, a 
strong CYP 1 A2 inhibitor, clozapine and norclozapine concentrations 
correlate with CYP3A activity (r = 0.44, P = 0.075; r = 0.63, P = 0.007, 
respectively). Carriers of the ABCBI 3435TT genotype had a 1.6-fold 
higher clozapine plasma concentrations than noncarriers (f = 0.046). In 
conclusion, this study has shown for the first time a significant in vivo 
raie of CYP2C 19 and the P-gp transporter in the pharrnacokinetics of 
clozapine. CYP1A2 is the main CYP isoform involved in clozapine · 
metabolism, with CYP2C19 contributing moderately, and CYP3A4 
contributing only in patients with reduced CYPl A2 activity. In addition, 
ABCBI, but not CYP2B6, CYP2C9, CYP2D6, CYP3A5, nor CYP3A7 
polymorphisms, influence clozapine pharinacokinetics. 
Key Words:· clozapine, plasma concentration, CYPIA2, CYP2Cl9, 
CYP3A4, ABCB 1 
(J Clin Psychopharmaco/ 2009;29: 319-326) 
B ecause of the risk ofhematologic adverse effects, clozapine is available as a second-line atypical antipsychotic drug despite . 
its efficacy being conside.red superior to that of other anti-
psychotics. 1 However, inadequate response to clozapine is es-
timated to be as high as 30%.2 Severa! studies3•4 confirmed 
the existence of a therapeutic window for clozapine and low 
plasma concentrations, despite adequate dosing, might explain 
some of .the cases of nonresponse. High plasma concentrations 
are risk factors for si de effects such as seizures. 5 
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Genetie and environmental factors contribute to the high 
interindividual variability in clozapine plasma concentrations.6- 8 
In vitro studies suggest that cytochrome P4501A2 (CYP1A2) 
is the most important CYP isoform contributlng to clozàpine 
N-demethylation, leading to the formation of the main active 
metabolite norclozapine. 9 Because smoking in duces c·yp 1A2, 10 
this is in agreement with the lower plasma concentrations of 
clozapine measured in heavy smokers as compared with non-
smokers. According to in vitro studies, CYP2Cl9 and CYP3A4 
could also be of considerable importance in the metabolism of 
clozapine,9 In vivo, CYP3A-inducing drugs such as càrbamaz-
epine1 1 reduce clozapine plasma concentrations, but it is un-
clear which CYP3A isoforms (ie, CYP3A4, CYP3A5, and/or 
CYP3A 7) are implicated in clozapine nietabolism. 
CYP2D6 probably plays a minor role in clozapine metab-
olism. 9 Indeed, the pharmacokinetics of clozapine was not 
significantly different · between 5 CYP2D6 poor metabolizers 
(PMs) and 5 extensive mètabolizers (EMs) receiying a singl,e 
oral dose of 10 mg clozapine. 12 Similarly, and in contradiction to 
in vitro data,9 clozapine pharmacokinetics was not significantly 
different between CYP2Cl9 EMs and PMs receiving a single 
oral dose of 1 O mg clozapine. 12 Finally, an in vitro study sug-
gested that clozapine is a substi'ate of the P-glycciprotein (P-gp) 
transporter, encoded by the ABCBJ gene,13 a finding that was 
subsequently contradicted. 14 No in vivo study has yet evaluated 
whether genetic polymorphisms of the ABCB 1 gene 15 influence 
clozapine plasma concentrations. 
The aim of this study was to examine the in vivo influ-
ence of genetic polymorphisms of CYP isoforms (CYPJA2, 
CYP2B6, CYP2C9, CYP2Cl9, CYP2D6, CYP3A4, CYP~A5, 
and CYP3A 7) and ABCBJ on steady-state plasma concentrat10ns 
ofclozapine. As the activities ofCYP1A2 and CYP3A are only 
partially reflected by geriotyping tests, patients were also Rheno-
typed with caffeine (CYP1A2) and midazolam .CCYP3A). 16 '!'he 
impact of environmental factors such as smokmg or comedtca-
tions was .invéstigated, Finally, as weight gain is one of the major 
side effects of clozapine and a risk factor for metabolic syn-
, b . !' t d. th' ffi t 17 18 drome, and as norclozapme may e 1mp tca e m ts e ec , · 
we examined this possible association. 
MATERIALS AND METHODS 
Patients 
Seventy~five inpatients ftoin 2 psychiatrie clinics, aged 
18 years 0~ older on stable clozapine treatment and unchanged 
comedication fo; at least 2 .wee~s (4 .we~ks for fluoxet.ine) 
were included in the study.- Exclus10n cntena were any senous 
uncontrolled illness, any organic ps~çhiatric ~llness, or su~-
t ce dependence. To ensure compltanèe, patients took thetr 
s and' t' nder supervision of a nurse for 4 days before me 1ca 10n u . . 
bl d 1. The study was approved by the local ethtcs oo samp mg. , (K" · fi Id d 
'tt f the 2 participatmg centers ontgs e en an commt ees o 
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Prilly-Lausanne). Written infonned consent was obtained from 
al! patients or their legal represenfative. · 
Blood Sampling 
On the moming ofday 1, before first drug intake, 75 µ,g oral 
midazolam was given to the patients for CYP3A phenotyping. 16 
A blood sample was taken 30 minutes later for determination of 
l'OH-midazolam/midazolam plasma ratio 16 and trough cloza-
pine and norclozapirie plasma concentrations. They then re-
ceived their usual medication, together with 200 mg caffeine for 
CYP1A2 phenotyping. 19 A second qlood sampling was per-
fonned 6 hours later for detem1ination of the paraxanthi11e-
caffeine plasma ratio. 19 No caffeine-containing food or beverage 
was allowed on the test day until after the second blood sam-
pling. Plasma, after centrifugation, and K-EDTA whole blood 
samples were kept frozen.at -20°C until analysis. Measurement 
ofclozapine and rtorclozapine plasma concentrations was repeated 
on day 7 to control compliance and exclude within-subject var-
iability. Because there were no significant differences between 
them (data not shown), results are expressed as the mean of the 
2 blood samplings. 
Assays of Drugs 
Clozapine and norclozapine concentrations were detennined 
by gas chromatography with a nitrogen-phosphorus detector.20 
Fluvoxamine,21 midazolam, ·and l'OH-midazolam16·22 caffeine 
and paraxanthine20 were measured by gas chromatography-mass 
spectrometry. Measured clozapine and norclozapine plasma con-
centrations were corrected by clozapine daily dose and hereafter 
are referred to as plasma concentrations. 
Genotyping 
· Genomic DNA was extracted from EDTA blood samples 
with the FlexiGene DNA Kit (Qiagen, Hombrechtikon, Switzer-
· 1and). Al! the single-nucleotide polymorphisms (SNPs), with the 
exception of CYP2D6*5 and CYP2D6*xN, were detected by 
real-time PCR with 5' -nuclease allelic discrimination assays 
(AB! PRISM 7000 Sequence Detection System; Applied Bio-
systems, Rotkreuz, Switzerland) with primers and probes ob-
tained from Applied Biosystems. The CYP JA2*1 F, CYP2B6*4, 
CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2C9*2, 
CYP2C9*3, CYP2Cl9*2, CYP2CJ9*3, CYP2D6*3, 
CYP2D6*4, CYP2D6*6, CYP3A4*1B, CYP3A5*3, ABCBJ 
61A>G, 2677G>T, and 3435C>T SNPs were analyzed as pre-
viously described.20·23 CYP2D6 gene deletion (allele *5) and 
duplication/multiduplication (allele *xN) were analyzed by quan-
titative real-time polymerase chain reaction (PCR) and long PCR, 
respectively.23 
CYP3A7*1C (-262T>A and -270T>G) allele was deter-
mined as previously described.24 CYP2C19*17 (-806C>T) 
allele was determined using the following primers, GTTTG 
GAAGTTGTTTTGTTTTGCTAA (forward), CATCGTGGCG 
CATTATCTCTT (reverse), and labeled probes, 6-FAM-
TTCTCAAAGcATCTCT-MGBNFQ; and VIC-TTCTGTTCT · 
CAAAGtATCT-MGBNFQ. The 25 µ,L PCR mixture contained 
12.5 µ,L TaqMan Universal PCR Master Mix (Applied Bio-
systems), 900 nM of each primer, 200 nM of each TaqMan 
minor groove binder nonfluorescent quencher probe, and 40 ng 
(100 ng for CYP2C19*17) of genomic DNA. After an activation 
step comprising AmpErase (50°C for 2 minutes) and AmpliTaq 
Gold enzyme activation (95°C for 10 minutes), 60 PCR 
cycles (50 cycles for CYP2CJ 9* 17) were performed with 
15 seconds at 92°C and 1 minute at 58°C (1.5 minutes at 
60°C for CYP2C19*17). CYP3A4 rs4646437C>T was ana-
320 1 www.psychopharmacology.com 
lyzed with commercial TaqMan Drug Metabolism Genotyping 
Assays according to the manufacturer's instructions (Assay Ids 
C_32306227_10; Applied Biosystems). 
Clinical Assessments 
Routine clinical chemistry and hematologic parameters 
were measured at baseline. Ali· patients underwent a physical 
examination at screening; their medical history was recorded, 
and psychiatrie and somatic diagnoses were confinned. On 
days 1 and 7, vital signs, weight, spontaneously repotted adverse 
events, and lifestyle factors (smoking, caffeine, and grapefruit 
intake) were noted. Weight gain data were collected retrospec-
tively from the patient's medical files. 
Statistical Analysis 
Clozapine and norclozapine blood concentrations were com-
pared between different genotypes by nonparametric analyses 
(Kruskal-Wallis test for >2, Mann-Whitney U test for 2 groups). 
Correlations between plasma concentrations and CYP1A2 or 
CYP3A activity were assessed by Speannan test, and multivariate 
analyses were perfonned using linear regression' · (backward 
method). A P < 0.05 was considered to indicate statistical 
significance. Ali statistical tests were perfonned in the whole 
group of patients and in the 2 subgroups with and without 
fluvoxamine as inhibition by fluvoxamine could mask the 
potential influence of other factors. Statistical analyses were per-
fonned using SPSS version 15.0 (SPSS, Inc, Chicago, Ill). For 
ABCBJ polymorphisms, Hardy-Weinberg equilibrium was tested, 
and linkage disequilibrium (Lewontin's D'coefficient) · was 
estimated with STATA (version 10; Stata Corporation, College 
Station, Tex). Haplotypes were inferred using the haplo.em func-
tion in R (http://www.r-project.org/), which uses expectation-
maximization algorithm. As none of the inferred haplotypes had a 
posterior probability below 98%, haplotype uncertainty can be 
considered as minimal. Genetie association studies were con-
ducted using the haplo.score function in R (which uses gener-
a!ized linear models and takes haplotype uncertainty into account) 
with an additive effect and a Gaussian distribution for the trait. 
RESULTS 
Patient Characteristics 
Seventy-five patients (39 men and 36 women; 73 white, 
1 Asian, and 1 black African) participated in the study. Their 
median age was 44 years (mean, 48 years; SD, 17 years; range, 
20-90 years). The majority were diagnosed with schizophrenic 
disorders (n = 73), one with bipolar disorder, and one with 
dementia of unknown etiology. Thirty-three patients presented 
with 1 or more somalie comorbidities, including 12 who expe-
rienced arterial hypertension. Four patients developed diabetes 
during clozapine treatment, and 4 were diabetic before taking 
clozapine for the first time. Treatment was generally well tol-
erated; the most frequent complaints were hypersalivation and 
weight gain. · · 
The median weight at entry to the study was 79 kg (range, 
52-128 kg; 74.5 kg and 83 kg, for women and men, respec-
tively). The median body mass index was 27.4 kg/m2 (range, 
19.1-36.6 kg/m2). Thirty-two patients (43%) gained 10% or 
more oftheir starting body weight during the course of clozapine 
treatment, with the maximum increase being 97% for 15 years 
for a male aged 32 years with a body mass index of36.6 kg/m2. 
Three patients lost weight, 25 remained stable, and 13 increased 
their weight slightly to moderately (<10% of body weight); for 
2 patients, the initial body weight was unknown. 
© 2009 lippincotl Williams & Wilkins 
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Plasma Concentrations of Clozapine · 
and/or Norclozapine, Comedications and 
Clinical Variables · 
The median clozapine daily dose was 250 mg (range, 
25-800 mg). Six patients received clozapine monotherapy; 
17 patients (23%) had comedication with the strong CYP1A2 
and moderate CYP3A and 2C 19 inhibitor fluvoxamine (dose 
range, 25-300 mg/d). 25 •26 The median trough plasma concen-
trations of clozapine and norclozapine were 1.14 ng/mL x mg 
(range, 0.15-6.24 ng/mL x mg) and 0.60 ng/mL x mg (range, 
0.04-2.36 ng/mL x mg) in the whole group of patients 
and 0.99 ng/mL x mg (range, 0.15-2.88 ng/mL x mg) and 
0.49 ng/mL x mg (range, 0.04-1.28 ng/mL x mg) in the group 
of patients without fluvoxamine, respectively. The median clo-
zapine, norclozapine, and clozapine + norclozapine plasma 
concentrations were 3.5-, 2.4-, and 3.3-fold higher, respectively, 
in the group with fluvoxamine as c_?7mpared with the_froup 
without fluvoxamine (P ;= 4.9 x 10 , P = 1.3 x 10 , and 
p = 1.1 X 1 o-6, respectivety). Correlations (logarithmic regres-
sions) were observed between fluvoxamine plasma concentra-
tions and clozapine (r2 = 0.65), norclozapine (r2 = 0.11), and 
clozapine + norclozapine (r2 = 0.52) plasma concentrations 
(Fig. 1 ). In addition, this figure suggests saturation of inhibition 
in the range of 50 to 1 OO ng/mL of fluvoxamine. In a·greement 
with a strong inhibition of CYP1A2 activity by fluvoxamine, 
. the median paraxanthine-caffeine ratios were 0.72 (range, 
0.19-3.12) and 0.33 (range, 0.08-3.49) in the groups of patients 
without and with fluvoxamine, respectively. Flattenirig of the 
correlati01~ curve (power regression, r2 = 0.71) between fluvox-
amine plasma concentrations and paraxanthine-caffeine ratios 
suggests saturation of the inhibition of CYP1A2 activity with 
increasing fluvoxamine plasma concentrations (Fig. 2). 
A group of patients was identified with other possibly rel-
evant comedications (maximal dose; number of patients): ser-
traline27 (150 mg/d; 6), paroxetine28 (40 mg/d; 3), fluoxetine29 
(20 mg/d; 1), levomepromazine30 (150 mg/d; 3), amlodipine 
(10 mg/d; 2), phenytoin31 (300 mg/d; 1), and omeprazole32 
(20 mg/d; 1). There was no significant effect of these comed-
ications on clozapine (P > 0.3), norclozapine (P > 0.9), or 
clozapine + norclozapine (P > 0.6) concentrations when con-
sidered individually or as a group. Sex and age in the total study 
population did not seem to influence clozapine plasma con-
Fluvoxamine plasma levels [ng/ml] 
FIGURE 1. Correlations (logarithmic regressions) between 
fluvoxamine plasma levels. and (111) dozapine (.y= 0.84Ln(x) + 0.88; 
r2 = 0.65), (A) norclozapine (y= 0.11 Ln(x) + 0.85; r2 = 0.11) 
and (o) clozapine + norclozapine (.y= 0.96Ln(x) + l.73; r2 = 0.52) 
d.ose-normalized plasma levels. 
© 2009 Lippincott Williams & Wilkins 
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FIGURE 2. Correlation between fluvoxamine plasma levels and 
CYP1 A2 activity measur.ed by the paraxanthine-caffeine ratio 
(power regression: y= 1.62 x-0·51 ; r2 = 0.71 ). The outlier 
corresponds to a patient with a CYP2D6 ultrarapid metabolizer 
polymorphism with very low fluvoxamine plasma levels. 
centrations (P = 0.34 and P = 0.43, respectively; data not 
shown). However, when excluding patients taking fluvoxa-
mine, women had significantly higher clozapine but not nor-
clozapine (P = 0.12, data not shown) plasma concent!ations 
(median, 1.11 [range, o'.18-2.88) ng/mL x mg vs 0.61 [range, 
0.15-2.72) ng/mL x mg, in women and men, respectively, 
p = 0.027). 
Forty-five patients were smokers (26 men and 19 women), 
and 30 were 110nsmokers (13 in en and 17 women). The number of 
cigarettes smoked per day ranged from 1 to 60 (median, 20). 
Smoking induces·CYP1A2 as shown by the 1.5-fold )ligher 
median paraxanthine-caffeine ratio (P ':' 0.031) in smokers (0.74 
[range, 0.08-3.49)) compared with nonsmokers (0.50 [range, 
0.09-1.15)). Lower norclozapine (median, 0.49 ng/mL x mg vs 
0.67 ng/mL x mg; P= 0.039), but not clozapine (1.03 ng/mL X mg 
vs 1.30 ng/mL x mg; P = 0.175), plasma concentrations were 
measured iri smokers compared with nonsmokers. As expected, 
this effect was more pronounced in the group without fluvox-
amine, where the influence of smoking was also significant on 
clozapine plasma concentrations (median, 0.72 ng/mL X ~g vs 
1.21 ng/mL x mg, in smokers and nonsm?kers, respectlv<;ly, 
p = 0.011). The effect of smoking on clozapme or norclozapme 
plasma concentrations was not related to the number (>20, 11~20, 
6-10, ::;5) of cigarettes smoked perday (data ?o~ ~hown). 
Because only 3 patients drank grapefruit JU!Ce, ~nd ail but 
2 had regular caffeine · intake, the effec~ of grapefruit .and caf-
feine on clozapine plasma concentrat10ns could not be de-
tennined. In contrast to 2 previous stud!es,17'
18 
there was no 
significant correlation between norclozapme plasma levels (not 
correèted by dose) and weight gain (r = O.l l, P = 0.38) norafter 
subgroup analysis of nonsmokers (r = 0.28, P = 0.14) and 
smokers (r = -0.07, P = 0.65). 
CYP and ABCB1 Genotyping 
The observed genotype frequencies of CYPIA2, CYP1B6, 
CYP2C9, CYP2Cl9, CYP2D6, CYP3A4, CYP3A5, fYf3A7, 
d ABCBJ are presented in Table l. They ... an~. ~\m!lar tp 
an . 1 described in white populations. (hJtp://www, thos~I ~rev~~us {33,34 and ail the SNPs are in. Har<!y-WeinP:erg· 
~y~~i:rie;~ 1;0~ the white subsample (n ~·. 73): ~I\ 3• SN;f~ of t~e ABCB 1 genes are in strong linkage d1se~ui11bnu';B: ~~ pre-
. 1 re orted. 15 . >> : ·• · r • 
v10us y fn the whole patient group \~ = 75l ~~~ :f!,i-1-
. · 'fi ntly influenced clozaptJ1e .. (R.:G . butnot 
notypes s1gnt ca . ·. .· ·· .:·, ...... 
· . h · ed reproduction of t~ Copyright© 2009 Lippincott Williams & Wilkins. Unaut onz • 
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TABLE 1. Frequency of CYP1A2*1F, CYP286, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4, CYP3AS, CYP3A7, and ABCB1 
Genotypes in 73 White Patients Treated With Clozapine 
95% Confidence 
Genotypè n Frequency lnterval (%) 
CYP1A2*1F 
*11*1 8 10.9 4.8-20.5 
*11*1F 31 42.5 31.0-54.6 
*1F/*1F 34 46.6 34.8-58.6 
CYP2B6 
*11*1 30 41.1 29.7-53.2 
*11*4 1.4 0.03-7.4 
*1/*5 8 10.9 4.8-20.5 
*11*6 20 27.4 17.6-39.1 
*11*7 4 5.5 1.5-13.4 
*51*5 2 2.7 0.3'-9.5 
*61*6 8 10.9 4.8-20.5 
CYP2C9 
*11*1 51 69.9 58.0-80.1 
.*11*2 11 15.1 7.8-25.4 
*11*3 8 10.9 4.8-20.5 
*21*2 1.4 0.03-7.4 
*21*3 2 2.7 0.3-9.5 
CYP2C19 
*11*1 24 32.9 22.3-44.9 
*11*2 .17 23.3 14.2-34.6 
*11*17 18 24.6 15.3-36.1 
*21*2 4 5.5 1.5-13.4 
*2/*17 4 5.5 l.5-13.4 
*171*17 6 8.2 3.1-17.0 
CYP2D6 
*11*1 40 54.8 . 42.7-66;5 
*11*3 4 5.5 1.5-13.4 
*11*4 16 21.9 i3.1-33.1 
*11*5 3 4.1 0.9-11.5 
*11*6 1 1.4 0.03-7.4 
*11*xN 4 5.5 1.5-13.4 
*41*4 4 5.5 1.5-13.4 
*4/*xN 1.4 0.03-7.4 
CYP3A 
CYP3A5*3 
*11*1 1.4 0.03-7.4 
*11*3 8 '10.9 . 4.8-20.5 
*3/*3 64 87.7 77.9-94.2 
CYP3A7*1C 
*11*1 66 90.4 81.2-96.1 
*1/*1C. 6 8.2 3.1-17.0 
*1C*1C 1.4 0.03-7.4 
CYP3A4 rs4646437 (intron 7) 
cc 58 79.4 68.4-88.0 
CT 14 19.2 10.9-30.1 
TT 1.4 0.03-7.4 
ABCB1 
61A>G 
AA 71 97.3 90.5-99.7 
AG 2 2.7 0.3-9.5 
2677G>T (exon 21) 
GG 25 34.2 23.5-46.3 
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TABLE 1. (continued) 
95% Confidence 
Genotype n Frequency lnterval (%) 
GT 38 52.1 40.0-63.9 
TT 10 13.7 6.8-23.8 
3435C>T (exon 26) 
cc 18 24.6 15.3-36.! 
CT 40 54.8 42.7-66.5 
TT 15 20.5 12.0-31.6 
norclozapine (P = ·0. l 8S) plasma concentrations (Figs. 3A, B ), 
with a 2.3-fold higher median clozapine concentrations in PMs 
(*21*2 genotype, n = 5, 2.58 ng/mL x mg [l.10-5.98]) than in 
extensive metabolizers (non-*2/*2 genotypes, 1.11 ng/mL x mg 
[0.15-6.24]) and 1.9-fold (P = 0.057) higher clozapine + 
norclozapine levels. Similarly, between carriers of the * 17 allele 
associated with an increased CYP2C 19 activity (* 171* 17, 
*1/*17) and PMs, the differences were 2.3-, 1.9-, and 1.6-fold, 
resp~ctively, for clozapine (P = 0.033), clozapine + norclozapine 
(P = 0.039), and norclozapine (P = 0.112). On the other hand, 
no significant differences in clozapine (P = 0.558), norclozapine 
(P = 0.186), and clozapine + norclozapine (P = 0.407) plasma 
levels were found between the carriers of the * 17 allele ( * 171* 17, 
* 11* 17) and extensive metabolizers (* 11* 1, * 11*2, *21* 17; 
data not · shown). In the smaller group of patients without 
fluvoxamine, significant differences were observed between 
CYP2C19 *11*1, *11*17 or *171*17 and *2/*17, *11*2 or *21*2 
individuals for clozapine (P = 0.027), norclozapine (P = 0.074), 
and the sum of both (P = 0.042). 
In the whole patient group (n = 75) ABCB1 3435 G>T 
polymorphism significantly influenced clozapine plasma concen-
trations (P = 0.046), with a 1.6-fold higher median clozapine con-
centrations in 3435TTgenotype (n = 16; median, 1.6 ng/mL x mg 
[range, 0.27-5.98 ng/mL x mg] in TT genotypes; n = 59; 
median, l.l ng/mL x nig [range, 0.15-6.24 ng/mL x mg) in 
CCICT genotypes). Statistical analysis on the 61 A>G polymor-
phism was not performed because of the low observed genetic 
variability (Table 1). No significarit influence of the 2677 G>T 
polymorphism on clozapine plasma concentration was observed 
(data not shown). In addition, norclozapine and clcizapine + 
norclozapine plasma concentrations did no! differ significantly 
between different genotypes (2677G>T and 3435C>T) (data 
not shown). Haplotype analysis revealed a trend toward higher 
clozapine concentration for carriers of 2677G-3435T haplo-
type (global score, 0.1; haplotype specific score, 0.01). Because 
of the small sample size when considering haplotypes, we 
also computed permutation tests (global empirical P = 0.10 
haplotype-specific empirical P = 0.01), which are in very close 
agreement with the asymptotic P based on a x2 distribution. 
Similar results were obtained after adjusting for sex and age 
(data not shown). 
Finally, other genetic polymorphisms were without influ-
ence on clozapine, norclozapine, or clozapine + norclozapine 
plasma levels: CYP 1A2 (P = 0.386, 0.632, and 0.533), CYP2B6 
(P = 0.664, 0.540, and Q.522), CYP2C9 (P = 0.252, 0.344, 
and 0.370), CYP2D6 (P = 0.464, 0.696, and 0.718); CYP3A4 
(P = 0.355, 0.341, and 0.444), CYP3A5 (P = 0.865, 0.206, 
and 0.627), and CYP3A7 (P = 0.586, 0.384, and 0.493), in 
the whole group (and in the patients without fluvoxamine 
[data not shown]). 
© 2009 Lfppincott Williams & Wilkins 
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FIGURE 3. A, Boxplot with median and interquartile range of clozapine plasma concentration (ng/ml x mg) according to .CYP2C7 9 
genotypes. Clozapine plasma level of 1 patient with the CYP2C19*7 /* 7 7 genotype was not detected. B, Boxplot with median and 
interquartile range of norclozapine plasma concentration (ng/ml x mg) according to CYP2C19 genotypes. Norclozapihe plasma level of 
1 patient with the CYP2C7 9* 7/*1 genotype was not detected. 
CYP1A2 and CYP3A Phenotyping and Clozapine 
Plasma Concentrations 
A strong correlation was observed betweeil CYP1A2 ac-
tivity and plasma ·concentrations of clozapine, norclozapine, 
and clozapine + norclozapine in the whole population 
(r = -0.61, P = 1·10-6; r = -0.48, P = 2·10-5; r = -0.59, 
P = 1·10-6), in the subgroup without fluvoxamine (n = 58) 
(r = -0.51, P = 5·10-5; r = -0.41, P = 0.001; r = -0.50, 
P = l · 10-4), and in the fluvoxamine subgroup (n = 17) 
(r = -0.69, P = 0.002; r = -0.39, P = 0.12; r = -0.64, 
p = 0.006). . 
No correlation was found between clozapine (r = -0.16, 
p = o. 16), norclozapine (r = -0.07, p = 0.58), and clozapine + 
norclozapine (r = -0.J 61, P = 0.172) plasma concentrations and 
CYP3A activity in the whole group. In the fluvoxamine 
subgroup, however, a weak correlation was found between 
. CYP3A activity and clozapine + norclozapine (r = 0.51, 
P = 0.038), a moderate correlation with norclozapine 
(r = 0.63, P = 0.007), and ·a trend with clozapine concentrations 
(r = 0.44, P = 0.075). · 
Multivariate Analyses 
Multivariate analyses .between clozapine, norclozapine, 
and clozapine + norclozapine plasma concentrations and the 
main factors potentially influencing their kinetic.s yielded 
the following models in the whole grciup of patients. For clo-
zapine, presence of fluvoxamine (P < 10-8), high fluvox-
amine concentrations '(P = 0.0001), low CYP1A2 activity 
(P = 0.0001), and .absence of CYP2Cl9 *17*17 or *171*1 
genotype (P = 0.008) were predictive of higher plasma 
concentrations (r = 0.84, P < 10- 17). Other variables such 
as fluvoxamine dose (P = 0.88), sex (P = 0.19), smoking 
(P = 0.29), CYP3A activity (P = 0.67), CYP3A4 rs4646437 
çillele T (P = 0.69), CYP1A2*1F/1F genotype (P = 0.32), 
ABCB1 2677TT génotype (P = 0.22), and ABCB1 3435TT 
·genotype (P = 0.17) did not significantly contribute to the 
mode!. For norclozapine, presence of fluvoxamine (P < 10-8), 
nonsmoking (P = 0.004), low CYP1A2 activity (P = 0.025), and 
absence of CYP2C19 *17*17 or *171*1 genotype (P = 0.036) 
were predictive of higher plasma concentrations (r = 0.72, 
© 2009 Lippincott Williams & Wilkins 
p < 10-9). For clozapine + norclozapine; presence of flu-
voxamine (P < 10-8), high fluvoxamine concentra'tions 
(P = 0.004), low CYP1A2 activity (P = 0.0001), and absence 
of CYP2C19 *17*17 or *171*1 genotypè (P = 0.012) were 
predictive ofhigher plasma concentrations (r= 0.82, P < 10-15). 
Similar models can be built including presence of CYP2Cl.9 *21 
*2 or *21* 1 genotype instead of absence of CYP2C19*17*17 or 
* 171* J genotype as a significant covariate for higher clozapine 
(P = 0.017) and clozapine + norclozapine (P = 0.030) plasma 
concentrations. 
DISCUSSION 
The measured trough plasma concentrations of clozapine, 
norclozapine, and clozapine + norclozapine corrected by daily 
dose presented a very wide interindividual variability, with a 41-, 
59-, and 23-fold variation, respectively. ·The determination of 
genetic' and· environmental factors contributing to this variation 
is therefore of clinical relevance considering the existence of a 
narrow therapeutic window for clozapine (350-600 ng/m9,3 
with plasma levels more than 800 to 1000 ng/mL bemg 
associated with increased risk of sicle effects such as convul-
sions. 5 Prevfous in vitro and in vivo studies suggested that the 
main CYP isoform mediating the metabolism of clozapine is 
CYP1A2. 8•35·36 Therefüre, modulation ofCYPlA2 activity will 
have a major influence on clozapine plasma levels a~d effect. We 
examined 4 factors believed to have a relevant influence on 
CYP1A2 activity: CYP1A2*1F polymorphism, t?e ~ffect .of 
smoking and caffeine consumption, a:nd comed1cat1on w1th 
fluvoxamine. · . 
· CYP1A2*1Fhas been associçited wit~ increased. CY~l~~· 
Ctl·v1'ty .i'n smokers possibly because of increased induc1b1h-a ' . . . 20,37 b t · t ty.20.37 In contras! to 2 prev1ous stud1es, u 1? agreemen 
with 2 others,38•39 we could not c?nfirm any infiuenc~ of 
CYP 1A2*1 F polymorphism on clozapine plasm~ concentrations 
or CYP1A2 activity, in the who~e group and. m the group. of 
k s· a strong influence of thts polymorph1sm on c!ozapme ~~~me: ~oncentrations seems therefore unlik~ly. On the other 
h d th l'mportant inducing effect of smoking on CYPIA2 an ' e . 40 . fi .d, d 
t. 'ty d clozapine metabolism . was co.n rme .. 1.n o .. ur stu y ac 1v1 an . . · · k d by the 1.5-fold higher CYP1A2 actlV!ty m.smo ers compare 
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with nonsmokers in ail patients and those without fluvoxamine 
comedication. Measured clozapine and norclozapine plasma 
levels in smokers compared with nonsmokers were thus 93% 
(not significant) and 77% (P = 0.039) in the w.hole group, and 
67% (P = 0.011) and 64% (P = 0.003) in the group without 
fluvoxamine. Iri.terestingly, the number of cigarettes smoked 
seemed to be of little relevance. Such a decrease in clozapine 
plasmà concentrations in smokers is in agreement with most 
other studies.39- 42 Considering the narrow therapeutic window 
of clozapine, therapeutic drug monitoring is recommended when 
smoking habits are changed, as cessation of smoking can lead 
to a significant rise in clozapine concentrations and risk of 
overdosage. 43 
In the present study, 23% of the patients were comedicated 
with the antidepressant. fluvoxamine. Such a high proportion 
is explained by the fact that in 1 study center (Kortigsfelden), 
patients not responding and/or intolerant to high doses of 
clozapine are switched to a combination of low-dose clozapine 
and fluvoxamine, with therapeutic drug monitoring to adapt 
clozapine doses. 17•20 •44 Fluvoxamine is a. strong CYPIA2 in-
hibitor, which is confirmed by the 2.2-fold higher paraxanthine-
caffeine ratios determined in the patients without fluvoxamine 
compared with those with fluvoxamine. Accordingly, fluvox~ 
amine markedly increases clozapine (3.5-fold) and norclozapine 
plasma concentrations (2.4-fold), indicating that it blacks the 
metabolism of both clozapine and norclozapine. The question 
arises whether the blocking effect of fluvoxamine on CYPIA2 
is dose dependent or is saturable at low doses. We investigated 
this in an earlier case series and concluded that comedication 
with 150 mg/d fluvoxamine has the same blocking effect as 
300 mg/d.45. This is confirmed by the relationship between flu-
voxamine, clozapine, ·and norclozapine plasma concentrations 
(Fig. 1), suggesting saturation of inhibition at low fluvoxamine 
plasma levels (approximately 50-100 ng/mL). Thus, a daily dose 
of approximately 1 OO mg fluvoxamine46 would be sufficient to 
have a major blocking effect on the metabolic pathways of clo-
zapine and norclozapine. Saturation of the inhibitory effect on 
CYP1A2 activity is also observed with paraxanthine-caffeine 
ratios at approximately 50 ng/mL fluvoxamine (Fig. 2). Finally, 
studies have suggested that caffeine consumption, in patiicular, 
when consumption fluctuates over time, can influence clozapine 
plasma concentrations, possibly by inhibition of CYP!A2.47 In 
the present study, as ail but 2 patients had règùlar intake of caf-
feine, the influence of caffeine on clozapine plasma concentra-
tions could not be verified. 
Conflicting results have been published on the implication 
and relative importance ofother CYP isoforms besicles CYP1A2 
in the metabolism of clozapine.9•12•48 We found no evidence of 
an effect ofCYP2B6, CY2C9, CYP2D6, CYP3A5, or CYP3A7 
on the steady-state kinetics of.clozapine or norclozapine. On the 
other hand, this seems to be the first study to demonstrate a 
significant in vivo involvement ofCYP2C19 in the pharmaco-
kinetics of clozapine, previously suggested by an in vitro study9 
but challenged by an in vivo study with a single oral low-dose of 
clozapine. 12 Thus, CYP2Cl9 PMs had 2.3-fold higher plasma 
concentrations of clozapine than patients with other CYP2C19 
genotypes. The absence of a significant influence of the 
CYP2C19*17 allele·could be attributed toits limited effect es-
pecially when present in 1 copy only.49 A possible explanation 
for the negative results observed in the single-dose (10 mg) 
study is that, with such a low oral dose, 12 only CYP!A2 was 
responsible for the metabolism of clozapine. 
îhe effect of CYP3A4 has been previously examined in 
interaction studies with CYP3A4 inhibitors and inducers. 11 •48 
Based on in vitro affinity constants, it has been suggested that its 
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raie becomes increasingly relevant with higher doses of clo-
zapine. 9 In our study, the dose ranged from 25 to 800 mg/cl, with 
a median of 250 mg/d. In the whole study population, there was 
no correlation between CYP3A activity and clozapine or 
norclozapine plasma concentrations. On the other hand, the ob-
served correlation between 1-0H-midazolam-midazolam ra-
tios and clozapine plasma concentrations in the fluvoxamine 
comedication group probably reflects the increasing impor-
tance of CYP3A4 in patients with blocked CYP!A2 activity. 
The very strong inhibition of clozapine metabolism by fluvox-
ainine can be explained by the fact that fluvoxamine is not only 
a strong CYP1A2 inhibitor but also a moderate inhibitor of 
CYP3A4 and CYP2C19. Finally, the present study is the first, 
to our knowledge, to suggest that clozapine plasma concentra-
tion. is significantly influ:enced by the genetic polymorphism of 
the ABCBJ gene, with higher concentrations measured in the 
3435TT genotype, a genotype previously associated with lo\\fer 
P-gp expression. 15 No conclusive results could be driven from 
the haplotype analysis because of the small number of patients 
in the haplotype groups. 
No serious adverse drug reactions were reported, but 
hypersalivation and weight gain were frequently reported to be 
troublesome and difficult to manage. Weight gain is considered 
one of the major si de effects of clozapine and is a risk factor for 
developing metabolic syndrome. Forty-three percent of patients 
gained 10% or· more body weight during clozapine treatment. 
Sorne authors found a reduced risk for weight gain· when com-
bining fluvoxamine with clozapine. 17 Another group found a 
correlation between norclozapine plasma concentrations and 
weight gain in nonsmoking patients. 18 These results·could not be 
confirmed in our study probably because of the small number of 
nonsmokers· included in the present study. Another limitation is 
that the duration of clozapine treatment and the nature of 'the 
'pretreatment could not be determined for ail patients and that 
some patients were comedicated with valproic acid and lithium, 
which are also associated with weight gain. Because of the im-
portant clinical problems associated with weight gain in patients 
treated with atypical antipsychotics,50 this should be examined 
further in prospective longitudinal studies. Finally, because of 
the limitation of the sample size, the results of the present study 
should be replicated by another study with a larger number of 
patients. 
In conclusion, this study examined thoroughly the in vivo 
implication of drug metabolizing enzymes and transporters in 
clozapine kinetics to explain its large interindividual variability. 
CYP!A2 is the major CYP isoform involved in clozapine 
metabolism in vivo, with CYP2C19 contributing to a moderate 
extent and CYP3A4 contributing in the presence of comedica-
tions that induce activity of this isozyme or when CYPIA2 is 
blocked by drugs such as fluvoxamine. ABCBJ genetic poly-
morphism also contributes to clozapine pharmacokinetic va~ 
riabiiity. To our· knowledge, this is the first study showing a 
significant in vivo raie ofCYP2Cl9 and the P-gp transporter in 
the clozapine kinetics. Besicles these genetic factors, environ-
. mental factors such as smoking or comedications (eg, fluvox~ 
amine) mafkedly influence the kinetics of clozapine. 
Considering the narrow therapeutic range, therapeutic drug 
monitoring of clozapine, in particular in the presence of 
nonresponse and/or side effects, is strongly recommended. 
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